Are hot flashes linked to heart risk?

There is emerging evidence that frequent or severe hot flashes (vasomotor symptoms), particularly when they are persistent, may be associated with less favorable cardiovascular risk markers in some studies. The association is still being studied and is not fully established, so it is best viewed as an emerging signal rather than a confirmed risk factor.

Does having hot flashes mean I will get heart disease?

No. The association is a statistical signal in research, not a prediction for an individual, and many women with hot flashes do not develop heart disease. It is one piece of context that, at most, reinforces the value of attending to cardiovascular health during the menopause transition.

What should I do if I have frequent or severe hot flashes?

Use it as a prompt to attend to cardiovascular health during the transition, ensuring your blood pressure, lipids, and glucose are monitored and that you are applying the proven prevention levers. Manage the hot flashes themselves with your clinician as a symptom matter. The cardiovascular response is the standard prevention approach, not a special intervention.

Does treating hot flashes reduce heart risk?

There is no good evidence that treating hot flashes, including with hormone therapy, reduces cardiovascular risk, and hormone therapy is not used for cardiovascular prevention. Symptom treatment and cardiovascular prevention are separate decisions, and the heart benefit comes from the proven prevention levers.

How does perimenopause affect cardiovascular risk?

The perimenopause transition, typically spanning the mid-40s to early 50s, is associated with accelerated cardiovascular risk accumulation. Estrogen withdrawal reduces nitric oxide production, increases arterial stiffness, shifts lipid profiles toward higher LDL and triglycerides, and promotes visceral fat deposition. The Healthy Women Study documented that LDL increased by 14 mg/dL on average across the menopause transition, an effect comparable to years of dietary change.

The Reproductive Clock

Hot Flashes and Cardiovascular Risk: An Emerging Signal

Frequent or severe hot flashes may signal less favorable cardiovascular risk. What the evidence supports and what it does not about this association.

Job Mogire, MD, FACP, FACC · Medically reviewed June 15, 2026

Hot flashes are the most recognized symptom of the menopause transition, but they are not only a comfort issue. An emerging body of research has begun asking whether frequent or severe vasomotor symptoms carry information about cardiovascular health, not just thermoregulatory discomfort. 3 / Early The evidence is real enough to take seriously and incomplete enough to state precisely: this is an early signal, not an established causal relationship, and the distinction matters.

The Mechanism

A hot flash is not a vague sensation. It is a measurable physiological event, and understanding what the body does during one is the starting point for understanding why cardiovascular researchers have become interested.

The underlying trigger is a narrowing of the thermoregulatory zone in the hypothalamus, the temperature band within which the body does nothing. When estrogen declines, this zone compresses, so that very small rises in core temperature cross the threshold and trigger a heat-dissipation response. The neurons most implicated are the KNDy neurons (kisspeptin-neurokinin B-dynorphin) in the hypothalamic arcuate nucleus, which modulate the activity of gonadotropin-releasing hormone (GnRH) neurons. As estrogen feedback to these neurons decreases, they become hyperactive, and that hyperactivity appears to lower the thermoregulatory trigger point.

What follows is a real vascular event. The cutaneous blood vessels dilate, core temperature drops measurably, skin conductance rises, and the woman experiences the characteristic heat and flush spreading upward from the chest. Researchers can detect and quantify this with ambulatory skin conductance monitors; women are not imagining the sensation, nor exaggerating it. A hot flash registers on instruments.

During that same episode, the sympathetic nervous system is activated. Norepinephrine rises. Heart rate increases transiently. The cardiovascular system, in other words, is involved in every hot flash, not as a passive bystander but as an active participant. This is where the cardiovascular hypothesis begins: if a woman is having five, ten, or more hot flash episodes per day or per night, she is experiencing repeated bursts of sympathetic activation and peripheral vascular change, potentially dozens of times each day.

The specific concern raised by researchers is about vascular reactivity and endothelial function. The endothelium, the thin inner lining of blood vessels, responds to sheer stress and chemical signals, and it plays a central role in long-term cardiovascular health. Repeated cycles of vasodilation and autonomic activation may, over time, affect how well the endothelium functions. This is a hypothesis grounded in plausible biology, and some preliminary evidence supports it, but the link between repeated vasomotor episodes and lasting vascular change in humans remains incompletely established.

A second mechanism, independent of direct vascular effects, runs through sleep. Nocturnal hot flashes fragment sleep architecture. Mitchell and colleagues documented disrupted polysomnography patterns associated with nocturnal vasomotor symptoms. This matters because poor sleep quality is not a minor inconvenience from a cardiovascular perspective: a meta-analysis by Cappuccio and colleagues published in the European Heart Journal in 2011 found that short sleep duration (fewer than six hours) was associated with a 48% increased risk of cardiovascular events. Sleep disruption is not a soft endpoint, and if frequent nocturnal hot flashes reliably disrupt sleep, that pathway alone is worth taking seriously.

A third overlay is that estrogen loss itself is a known cardiovascular risk factor. Estrogen has direct favorable effects on lipid profiles, vascular tone, and endothelial function. When it declines, the cardiovascular environment shifts regardless of whether a woman has hot flashes at all. Research published by Wildman and colleagues from the SWAN (Study of Women’s Health Across the Nation) cohort in 2008 documented significant metabolic and lipid changes during perimenopause independent of vasomotor symptoms. This complicates interpretation: women with severe vasomotor symptoms may be experiencing a more complete or abrupt loss of estrogen protection, meaning hot flash severity could function partly as a marker of estrogen decline severity, rather than as an independent cause of cardiovascular harm.

What the Evidence Shows

The research associating vasomotor symptoms with cardiovascular risk markers has accumulated over roughly two decades. It is worth reading with the full picture: methodologically, most of this is observational, confounding is a serious problem, and mechanistic studies in humans are limited in number.

The most important ongoing data source is the SWAN study, a multi-site NIH-funded longitudinal cohort that has followed women through the menopause transition since the mid-1990s. Rebecca Thurston and colleagues have published multiple analyses from this cohort examining the relationship between vasomotor symptoms and cardiovascular risk markers. A 2017 paper in Menopause by Thurston et al. found that early-onset vasomotor symptoms, those that begin before the final menstrual period, were associated with higher cardiovascular risk markers, while late-onset vasomotor symptoms showed a weaker association. Timing, not just frequency, appears to matter. The same group found associations between more frequent and severe hot flashes and higher subclinical atherosclerosis markers, including carotid intima-media thickness and arterial calcification, in multiple SWAN analyses. These are structural markers, not just biochemical ones, and they carry predictive weight in cardiovascular epidemiology.

Earlier mechanistic evidence came from Bechlioulis and colleagues, who published in the European Heart Journal in 2010 a study finding that frequent vasomotor symptoms were associated with impaired endothelial function measured by flow-mediated dilation. Flow-mediated dilation is a noninvasive ultrasound measurement of how well a vessel dilates in response to increased blood flow; it reflects endothelial health. Impaired flow-mediated dilation precedes clinical cardiovascular disease in other populations. This was an early paper, with limitations of sample size and design, but it provided the first direct mechanistic evidence connecting hot flash frequency to a measurable marker of vascular function.

Epidemiological evidence for clinical events comes from a Dutch study by Gast and colleagues published in Menopause in 2008, which found that frequent hot flashes were associated with increased risk of non-fatal myocardial infarction and stroke. The effect size was meaningful, though observational studies of this kind cannot exclude that women with more frequent hot flashes also differed in other cardiovascular risk factors.

That confounding concern is the central limitation of this entire literature, and it deserves direct statement. Women with more severe vasomotor symptoms may differ systematically from women with mild symptoms in ways that matter for cardiovascular health: higher baseline BMI, more sedentary lifestyle, metabolic syndrome, lower income, higher perceived stress. These factors are associated with both VMS severity and cardiovascular risk, and they are difficult to fully adjust for in observational research. The honest answer to “do hot flashes cause cardiovascular harm” is: we do not know. We know there is an association. We do not know how much of it is causal and how much is confounded.

The Women’s Health Initiative provides important context on the hormone therapy side of this picture, though its implications are frequently misread. A 2013 analysis by Manson and colleagues in the New England Journal of Medicine clarified what is now called the timing hypothesis: women who began hormone therapy within ten years of menopause, or before age 60, did not show increased cardiovascular risk. Women who began hormone therapy later in the menopause transition, when they were older and already at higher baseline risk, showed adverse cardiovascular signals. The WHI’s original findings were in that older, already-at-risk group, and the overcorrection that followed left many symptomatic women undertreated for years. The current evidence supports hormone therapy as safe for symptom relief in appropriate candidates, specifically healthy women within ten years of menopause onset. It does not support hormone therapy as a cardiovascular prevention strategy, and that distinction is firm.

Cardiologist's Note

I want to be specific about what I mean when I say this signal is early, because “early” can be read as either “preliminary” or “promising” and I mean the former, not the latter. The SWAN data are real. The Bechlioulis flow-mediated dilation findings are real. The biological plausibility is real. But the gap between “there is a statistical association between hot flash frequency and cardiovascular risk markers” and “hot flashes cause cardiovascular disease” is large, and we have not closed it. If a patient sits across from me and says she has been having ten hot flashes a day for two years, I do not tell her she is headed for a heart attack. I tell her that the research is interesting and that it makes attending to her cardiovascular health particularly worth her time right now.

What I am watching for in my patients with frequent or severe vasomotor symptoms is not something esoteric: it is blood pressure, lipid panel, fasting glucose, and whether she is sleeping adequately and moving her body. Those are the same things I watch for in every woman going through the menopause transition, because the transition itself carries cardiovascular significance regardless of hot flash severity. If her VMS are severe enough to significantly disrupt her sleep, that sleep disruption is a cardiovascular concern in its own right, and it is also a quality-of-life concern that she deserves to have addressed.

On hormone therapy: I have patients who have been told, often by well-meaning providers responding to the original WHI headlines, that they cannot have hormone therapy because it “causes heart attacks.” That was an incomplete reading of the evidence even in 2002, and it is not consistent with what we know now. For a healthy woman in her early 50s whose primary symptom is disrupted sleep and frequent hot flashes, hormone therapy is an appropriate conversation, and starting it within the window of the menopause transition does not appear to increase her cardiovascular risk. It also will not reduce it. These are two separate questions. What will reduce her cardiovascular risk is blood pressure control, a favorable lipid profile, not smoking, regular physical activity, and not carrying excess visceral weight. I make sure she understands that those are her heart levers, and that the hormone conversation belongs to the symptom discussion.

The patients I am most concerned for are those with significant nocturnal hot flashes who are not sleeping, who are fatigued, who are no longer exercising because they are exhausted, and who have let monitoring lapse. That cascade is where I see the cardiovascular picture worsen, not because of the hot flashes per se, but because of what they displace. Addressing the symptoms, whatever the method, often restores the ability to do the things that actually protect the heart.

Subclinical Atherosclerosis Imaging in Women With Vasomotor Symptoms: What Structural Studies Show

Beyond biochemical markers and symptom questionnaires, a parallel line of investigation has used structural imaging to ask whether frequent vasomotor symptoms are associated with detectable changes in arterial wall architecture. The findings add texture to the epidemiological associations but come with the same methodological caveat that characterizes this entire literature: observational data with multiple potential confounders and no randomized evidence to establish causation.

Carotid intima-media thickness, measured by high-resolution B-mode ultrasound, represents the combined thickness of the carotid artery’s innermost two layers, the intima and media. It is established as a noninvasive structural marker of subclinical atherosclerosis and arterial aging. Increased carotid intima-media thickness predicts future cardiovascular events in multiple population cohorts, and its progression over time has been used as a primary endpoint in cardiovascular prevention trials.

Thurston and colleagues published findings from the SWAN Heart ancillary study in Menopause in 2016, examining the relationship between vasomotor symptom frequency and carotid intima-media thickness in a subset of SWAN participants. Women with more frequent vasomotor symptoms, specifically those with ten or more episodes per day, had greater carotid intima-media thickness compared with women with fewer symptoms, after adjustment for cardiovascular risk factors, reproductive hormone levels, and lifestyle variables. The association held in multivariable analysis, providing structural support for the epidemiological signal previously based primarily on self-reported symptom frequency and biochemical markers.

El Khoudary and colleagues published related findings from the SWAN Heart study in Menopause in 2012, examining the relationship between vasomotor symptoms and aortic stiffness, measured using the pulse wave velocity technique. Higher hot flash frequency was associated with greater aortic stiffness in this cross-sectional analysis. Arterial stiffness is an independent predictor of cardiovascular events and reflects pathological changes in vessel wall elasticity that develop with atherosclerosis and aging.

Coronary artery calcification, measured by cardiac computed tomography and quantified as the Agatston calcium score, has also been examined in relation to vasomotor symptom history in several cohorts. Cross-sectional data from the SWAN Heart and related studies have shown associations between greater or earlier vasomotor symptom burden and higher calcium scores, though the cross-sectional nature of most available data precludes causal inference.

What these structural findings collectively suggest is that the association between frequent vasomotor symptoms and cardiovascular risk markers extends to imaging-based measures of subclinical disease, not just biochemical or clinical risk estimates. This strengthens the biological plausibility of the association without establishing causation. For the clinician and the patient, the practical implication is unchanged: frequent or persistent vasomotor symptoms provide context that makes rigorous cardiovascular monitoring appropriate, but they do not change which prevention strategies are effective or warranted.

What to Do This Week

Schedule a cardiovascular baseline if you do not have one from the past 12 months. This means blood pressure measurement, a fasting lipid panel, and fasting glucose or HbA1c. These are the markers that predict cardiovascular events, and the menopause transition is an appropriate time to make sure they are in view. You do not need a formal cardiology referral to start; a primary care appointment will cover the basics.
Take the sleep disruption seriously. If you are waking multiple times per night due to hot flashes, track roughly how many episodes you are having over a week, and bring that count to your clinician. Nocturnal hot flash frequency affects sleep architecture, and poor sleep quality carries its own cardiovascular burden. Symptom treatment for the hot flashes themselves, whether that is hormone therapy, non-hormonal options such as fezolinetant or low-dose paroxetine, or behavioral strategies, is a legitimate part of protecting downstream health, not just a quality-of-life nicety.
Have an honest conversation about hormone therapy if it is relevant to your situation. If you were told years ago that hormone therapy was ruled out because of heart risk, that conversation may be worth revisiting with current evidence. The relevant questions for your clinician are: where you are in the menopause transition, what your individual cardiovascular risk factors look like, and whether you are within the window where the timing hypothesis suggests safety. This is a clinical decision that depends on your specific picture, not a blanket yes or no.
Protect your exercise routine with the same seriousness you would a medication. Physical activity is among the most potent cardiovascular prevention tools available, and it is disproportionately common for women to stop exercising during periods of severe menopausal symptoms, both because of fatigue from sleep disruption and because of the logistics of managing symptoms during exertion. If hot flashes are making exercise harder, that is a concrete reason to address the symptoms, because losing the exercise habit has real cardiovascular cost.
Do not add a layer of cardiovascular anxiety to the symptom burden you are already carrying. The evidence reviewed here is real, and taking it seriously means attending to cardiovascular health monitoring. It does not mean interpreting every hot flash as a warning sign or adding health anxiety to an already difficult set of symptoms. The cardiovascular response to this signal is exactly the same as it is for any woman at the menopause transition: standard prevention, monitored consistently.

The picture that emerges from this research is not alarming, but it is worth understanding clearly. Frequent or severe vasomotor symptoms appear to be associated with less favorable cardiovascular markers in observational data, with multiple plausible biological mechanisms at work, and with enough evidence to say that frequent hot flashes are worth noting in the cardiovascular context. The appropriate response is to use that information as a prompt toward attentive, consistent cardiovascular monitoring, not to treat it as a diagnosis or a verdict. The prevention levers remain the same ones that have always existed, and the women who apply them consistently fare better regardless of their vasomotor symptom history.

Find out which signals are active in your own pattern.

Take the Women's Signal Check

Did this land?

The conversation

Join the men working through this in the open.